CLSA organized a multi-state life sciences association letter to House and Senate Leadership, expressing our strong concerns with recent legislative proposals that threaten to undermine America’s global leadership in biomedical innovation by introducing international reference pricing or foreign price controls.
On Oct 17, CLSA and Covington & Burling, LLP hosted Keith Flanagan, Director, and Maarika Kimbrell, Deputy Director, of FDA’s Office of New Drugs (OND) for a roundtable discussion on drug development.
On Sept. 19, House Speaker Nancy Pelosi (D-San Francisco) unveiled legislation in the form of the Lower Drug Costs Now Act (H.R. 3), an unprecedented sweeping proposal that would transfer most domestic drug pricing decision-making to U.S. and European government bureaucrats, and eviscerate the free market model that has promoted innovation, cures and treatments for millions of patients.
CLSA President & CEO Mike Guerra pens an op-ed in Morning Consult regarding the dangers of policymakers utilizing foreign price controls to lower drug costs. With growing bipartisan support for these schemes, CLSA is working to educate policymakers that importing price controls will do little to lessen the financial burden for patients. Rather, these short-sighted proposals will hinder access to needed treatments and discourage medical innovation in California.
CLSA was proud to once again sponsor and participate in this year’s 7th Annual Rally for Medical Research Hill Day on Sept. 19. This annual event brings together more than 300 participants, including patient advocates, researchers, and life sciences company representatives, to call on our nation’s policymakers to ensure for the National Institutes of Health (NIH) is a national priority.
CLSA leadership participated in an executive advocacy day on Capitol Hill on Sept. 19, that was coordinated by our national medtech association partner, AdvaMed. The purpose of the fly-in was to advocate for the full and permanent repeal of the 2.3 percent excise tax on medical device revenue that will go back into effect on January 1, 2020 if Congress does not act before the end of the year.
Congress will return from its annual summer District Work period (“August Recess”) after Labor Day on Sept. 9. Looking ahead to legislative agenda for the fall, healthcare, and more specifically drug pricing, is expected to remain a critical issue for lawmakers to address.
When Congress returns from the District Work period (“August recess”) in September, there will be only 10 legislative weeks remaining for Congress to take action to prevent the Medical Device Excise Tax from going back into effect on January 1, 2020. CLSA has worked closely with our membership, our national trade association partners, allied stakeholders and congressional champions to introduce the Protect Medical Innovation Act of 2019 (H.R. 2207), which would permanently repeal this innovation stifling tax.
After reaching a deal with the White House, on Thursday, July 25 – a day before Congress departs for the August District Work Period – the House of Representatives voted 284 to 149 to pass a bipartisan two-year budget and to extend the debt limit through July 31, 2021.
On July 16, Senator Kamala Harris (D-CA) released a plan proposing international price controls as part of her solution to lower drug costs. This latest action demonstrates growing bipartisan interest in using the dangerous concept of price controls as a mechanism for lowering list prices for pharmaceuticals in the U.S.